Mariluz
@monfortedelemos.es
Pneumology
Seccion de Neumologia, Hospital de Monforte de Lemos, Monforte de Lemos, Lugo, Epson
Scopus Publications
Scopus Publications
Mariluz Santalla Martínez and Manuel Loureiro Martínez
Elsevier BV
Psoriasis is a chronic inflammatory disease mainly affecting the skin. The pathogenic mechanism of this condition is largely due to overstimulation of CD4 Th1 and Th17 lymphocytes, which have a well-established role in the formation of sarcoid granulomas.1 We present the case of a 38-year-old woman with a diagnosis of severe psoriasis vulgaris, with a finding of mediastinal lymphadenopathies and ground glass infiltrates, finally diagnosed as sarcoidosis. A 38-year-old woman with a 9-year history of severe psoriasis vulgaris (Fig. 1) receiving treatment with topical corticosteroids. A chest radiograph and Mantoux testing were performed before starting systemic biological therapy. She had no respiratory symptoms, but the radiograph showed a chance finding of right hilar lymphadenopathies (Fig. 2A). The examination was completed with a chest computed tomography (Fig. 2B), showing pathologically enlarged hilar and mediastinal lymph nodes and bilateral ground glass parenchymal infiltrates. Angiotensin-converting enzyme levels were normal. Fiberoptic bronchoscopy was performed. Bronchial aspirate and bronchoalveolar lavage (BAL) cultures were negative, and cytology was also negative for malignancy. BAL immunophenotyping revealed a lymphocyte population composed
Mariluz Santalla-Martínez, Hermitas García-Quiroga, and Inés Navarro-Menéndez
Elsevier BV
Mariluz Santalla Martínez, Nagore Blanco Cid, and Raquel Dacal Quintas
Elsevier BV
The incidence and severity of lung toxicity reported in clinical trials with bortezomib, a synthetic anticancer drug, was low. However, since marketing, severe cases have come to light.1,2 We report the case of a 65-year-old female patient with a diagnosis of multiple myeloma (MM) presenting with acute dyspnea, fever and pulmonary infiltrates after receiving combined PAD chemotherapy (bortezomib, adriamycin and dexamethasone).
Raquel Dacal Quintas, Manuel Tumbeiro Novoa, María Teresa Alves Pérez, Mari Luz Santalla Martínez, Adela Acuña Fernández, and Pedro Marcos Velázquez
Elsevier BV
Abstract Objective To determine the frequency of obstructive sleep apnoea (OSA) and metabolic syndrome (MS) in normal weight patients and their characteristics, and to compare these with overweight and obese patients. Methods We studied all patients with suspected OSA referred to the sleep laboratory from January to December 2009. OSA was diagnosed when the apnoea-hypopnoea index (AHI) was >5 and symptoms were present. MS was diagnosed according to International Diabetes Federation (IDF) criteria. The patients were distributed into 3 groups according to body mass index (BMI): normal weight ( Results We studied 475 patients: 7.60% normal weight and 56.4% obese. Most patients in the normal weight group were women, snorers, non-smokers, non-drinkers and were significantly younger and with a smaller neck and waist circumference than obese and overweight patients. OSA was diagnosed in 90.10%: 77.70% normal weight. OSA in these patients was mostly mild, and there were differences between the diagnosis of OSA and the BMI classified. MS was diagnosed in 64.40%: 33.33% normal weight. There was a higher probability of MS as the BMI increased. OSA and MS frequency in normal weight patients was 22% and in obese patients was 70.52%. OSA in normal weight patients was related with gender and age. There was no relationship between OSA and MS, or between otorhinolaryngological malformations and OSA in normal weight patients. Eight normal weight patients with OSA were treated with continuous positive airway pressure (CPAP) therapy. Conclusions The frequency of OSA in normal weight patients was lower than in overweight and obese patients. The frequency of concomitant OSA and MS was lower in normal weight patients than in obese subjects. Normal weight patients were mostly women, younger and had no toxic habits. In normal weight patients, age and gender were predictive factors for OSA, but OSA and MS were not related.
Mariluz Santalla Martínez, Raquel Dacal Quintas, and Pedro Marcos Velázquez
Elsevier BV
Raquel Dacal Quintas, Manuel Tumbeiro Novoa, María Teresa Alves Pérez, Mari Luz Santalla Martínez, Adela Acuña Fernández, and Pedro Marcos Velázquez
Elsevier BV
Abstract Objective To determine the frequency of obstructive sleep apnoea (OSA) and metabolic syndrome (MS) in normal weight patients and their characteristics, and to compare these with overweight and obese patients. Methods We studied all patients with suspected OSA referred to the sleep laboratory from January to December 2009. OSA was diagnosed when the apnoea-hypopnoea index (AHI) was >5 and symptoms were present. MS was diagnosed according to International Diabetes Federation (IDF) criteria. The patients were distributed into 3 groups according to body mass index (BMI): normal weight ( Results We studied 475 patients: 7.60% normal weight and 56.4% obese. Most patients in the normal weight group were women, snorers, non-smokers, non-drinkers and were significantly younger and with a smaller neck and waist circumference than obese and overweight patients. OSA was diagnosed in 90.10%: 77.70% normal weight. OSA in these patients was mostly mild, and there were differences between the diagnosis of OSA and the BMI classified. MS was diagnosed in 64.40%: 33.33% normal weight. There was a higher probability of MS as the BMI increased. OSA and MS frequency in normal weight patients was 22% and in obese patients was 70.52%. OSA in normal weight patients was related with gender and age. There was no relationship between OSA and MS, or between otorhinolaryngological malformations and OSA in normal weight patients. Eight normal weight patients with OSA were treated with continuous positive airway pressure (CPAP) therapy. Conclusions The frequency of OSA in normal weight patients was lower than in overweight and obese patients. The frequency of concomitant OSA and MS was lower in normal weight patients than in obese subjects. Normal weight patients were mostly women, younger and had no toxic habits. In normal weight patients, age and gender were predictive factors for OSA, but OSA and MS were not related.